Genetic characterization of hepatitis C virus strains in Estonia: Fluctuations in the predominating subtype with time
| Autor: | Kaije Pruunsild, Tõnu Krispin, Karen Orgulas, Valentina Tefanova, Lars O. Magnius, Ludmilla Priimägi, Tatjana Tallo, Madis Ilmoja, Jelena Schmidt, Helene Norder |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Estonia Male Adolescent Patients Hepacivirus Hepatitis C virus Molecular Sequence Data Blood Donors Viral Nonstructural Proteins medicine.disease_cause Virus chemistry.chemical_compound Flaviviridae Species Specificity Risk Factors Virology Genotype medicine Humans Substance Abuse Intravenous NS5B Molecular Epidemiology biology Viral Core Proteins Incidence (epidemiology) virus diseases Hepatitis B biology.organism_classification medicine.disease Hepatitis C Hospitals Personnel Hospital Infectious Diseases chemistry RNA Viral Female 5' Untranslated Regions |
| Zdroj: | Journal of Medical Virology. 79:374-382 |
| ISSN: | 1096-9071 0146-6615 |
| Popis: | During the last decade, there has been a dramatic increase in intravenous drug use in young adults in Estonia with an increased incidence of both hepatitis B and C as a consequence. Since genetic data are limited regarding hepatitis C virus (HCV) strains in Estonia, the aim of the study was to characterize HCV strains in different risk groups to determine their relatedness to strains from other geographical regions. Three hundred fifty-three anti-HCV positive sera collected during 1994–2004 from hospitalized patients, blood donors and health care workers were used as source of HCV RNA. Two hundred nine (59%) of the sera were positive for HCV RNA by PCR directed to the 5′-UTR region. For 174 strains the HCV subtype was determined by analyses of the NS5B and/or the 5′UTR-core regions. 1b (71%) was the most common subtype followed by 3a (24%), 2c (2%), 1a (1%), and 2a (1%). The 1b and 3a strains were similar to strains from other regions of the former USSR. Within genotype 1b there were several HCV lineages. However, for 3a there seemed to be two separate introductions into Estonia. There was a relative shift from subtype 1b to 3a in 1999–2000 with a further replacement of 3a with 1b in intravenous drug users in 2001 and onwards (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text